Compass Therapeutics, Inc. CMPX
0.76 USD +0.07 (+10.84%)
At closeNov 6, 2026, 7:44 PM EST
0.77 +0.01 +1.94%
After hours · Nov 6, 7:44 PM ET
0.6714 Day range 0.7598
0.685 52-week range 6.69
- YTD
- -85.87%
- 1 year
- -81.03%
News
benzinga.com Compass Therapeutics To Present Data On Novel Mechanism Of Action For CTX-10726 At 41st Society For Immunotherapy Of Cancer Annual Meeting CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized…
globenewswire.com Compass Therapeutics to Participate in Upcoming November Investor Events BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
benzinga.com This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
benzinga.com Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8 Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
benzinga.com This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.- benzinga.com Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4 Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.
benzinga.com Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4 Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.
benzinga.com Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1 Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.
benzinga.com HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12 HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.
benzinga.com Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
benzinga.com Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA marketing application.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
benzinga.com Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.- benzinga.com Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6 Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
benzinga.com Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses…
benzinga.com Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today…- benzinga.com Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with…
- benzinga.com Compass Therapeutics Q1 EPS $(0.10), Inline Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.12) per share from the…
benzinga.com Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7 Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 guidance. European shares mixed, Asian markets close mixed.
benzinga.com US Stocks Mixed; Nasdaq Falls Over 100 Points US stocks mixed on Monday, Nasdaq falls 0.56% while Dow gains 0.06%. Energy shares up 1%. Domino's reports worse-than-expected results.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.
benzinga.com Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 9 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday 
benzinga.com This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Earnings Scheduled For August 11, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Why NextGen Healthcare Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market trading after gaining around 9% on Friday.- benzinga.com Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 729 companies set new 52-week lows.